Who is sponsoring NCT05262517?

NCT05262517 is sponsored by Pfizer.

What condition does NCT05262517 study?

NCT05262517 studies Temporomandibular Disorders (TMD).

What drugs are being tested in NCT05262517?

Interventions: Rimegepant, Placebo.

What is the status of NCT05262517?

NCT05262517 is currently TERMINATED.

Last reviewed 2024-05-16 · How we verify

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

NCT05262517 PHASE3 TERMINATED Results posted

The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of Temporomandibular Disorders (TMD), which are medical conditions involving the temporomandibular joint (the joint connecting the jawbone to the skull) and surrounding muscles and tissues.

Details

Lead sponsor	Pfizer
Phase	PHASE3
Status	TERMINATED
Enrolment	126
Start date	Thu May 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu May 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Temporomandibular Disorders (TMD)

Interventions

Rimegepant
Placebo

Countries

United States